it's bascisally the same formulation as what they've already used in a couple of other successful phase 1s. All they are changing is the mRNA in the delivery vesicle. I don't expect it to have any SAEs.
" And even if it affords protection against Covid-19, it probably won't against Covid-20 or 21."
but that's where their technology potentially has as advantage if it does happen to work. You just have to sequence the new strain, quick bit of cloning and transcription and you already have you're new vaccine. It's actually interesting how this would work with regards to approval as it would be a minor adaptation to the technology...would they still have to go through the full phase1-3?
News 
Market Data 
Discover 
AI
